Moderna: The Long View
What the filings say about its story, dilution and cash runway.
This page is information, not investment advice.
1. In one paragraph
Last updated Nov 12, 2026. Reflects the 10-K for 2025 and the 10-Q for Q3 2026.
Moderna makes messenger RNA (mRNA) vaccines and is developing mRNA cancer and rare-disease medicines. Almost all of its sales still come from COVID vaccines. In 2025 revenue was $1.94B (−40%) (10-K 2025):
- COVID vaccines (Spikevax and mNEXSPIKE) are sold to US wholesalers and pharmacies and to foreign governments.
- It also sells a vaccine against respiratory syncytial virus (RSV), mRESVIA; a flu plus COVID combination vaccine was approved in the EU in April 2026 and its flu vaccine, mFLUSIVA, in the US on Aug 5, 2026, for adults 50 and older (FDA).
- Its cancer vaccine, intismeran autogene, is developed with Merck, which shares costs and any profits equally.
| 2025 (disclosed; shares are our calculation) | Revenue | Share of total |
|---|---|---|
| COVID vaccines | $1,810M | 93% |
| RSV vaccine | $8M | 0.4% |
| Other revenue (stand-ready manufacturing, fees for keeping manufacturing capacity available, $80M, grants $22M, collaboration $13M, licensing $11M) | $126M | 6% |
| Product sales by customer location: US / Europe / rest of world | $1,165M / $50M / $603M | 60% / 3% / 31% |
In the first nine months of 2026 revenue was $1.85B, against $1.27B a year earlier; Moderna expects revenue to grow 15–25% in 2026, about half from the US and half from international markets (Q3 2026 release).
2. Story so far
Last updated Nov 12, 2026. Reflects filings and company releases through Nov 12, 2026.
In short: Moderna’s COVID vaccine took it from no product sales to $18.5B of revenue in 2021, and it spent $5.3B buying back stock in 2021–23. As COVID demand fell, revenue shrank to $1.9B in 2025 and it lost money every year from 2023; it cut costs, took a $600M secured loan and settled a patent dispute. In 2026 its personalised cancer vaccine succeeded in a late-stage melanoma trial, and the share price rose from about $30 to above $240 before falling back.
| Date | Milestone | Source |
|---|---|---|
| Dec 18, 2020 | ★ COVID vaccine authorised for emergency use in the US, Moderna’s first product | 10-K 2021 |
| 2021 | Revenue $18.5B, net income $12.2B; first buyback, $857M | 10-K 2021 |
| 2022 | Revenue $19.3B; $3.3B of buybacks | 10-K 2022 |
| 2023 | ★ Revenue falls 64% to $6.8B; net loss $4.7B. Last buybacks ($1.2B) | 10-K 2023 |
| May 2024 | RSV vaccine mRESVIA approved in the US | 10-K 2025 |
| May 2025 | Second COVID vaccine, mNEXSPIKE, approved in the US | 10-K 2025 |
| Nov 19, 2025 | $1.5B secured loan facility with lenders led by Ares; $600M drawn | 8-K |
| Jan 12, 2026 | Targets cash breakeven (cash inflows matching cash outflows) in 2028 and up to 10% revenue growth in 2026 | 8-K |
| Mar 3, 2026 | Settles Arbutus/Genevant patent suits: $950M, plus up to $1.3B depending on an appeal | 8-K |
| Jul 31, 2026 | Q2 results: cost and cash guidance improved; norovirus vaccine misses an interim test | Release |
| Aug 5, 2026 | Flu vaccine mFLUSIVA approved in the US | FDA, company release |
| Aug 19, 2026 | ★ Phase 3 melanoma trial of intismeran plus Merck’s Keytruda meets its main goal. Stock +177% that day (reported Yahoo Finance closes $62.96 → $174.38; our calculation)1 | Merck/Moderna release |
| Sep 1, 2026 | Sells $3.0B of 0% convertible notes (debt that can convert into shares, with settlement in cash, shares or both) due 2032 | 8-K |
| Oct 22, 2026 | ★ Full trial results: 42% lower risk of recurrence or death vs Keytruda alone. Stock −17.6% (reported Yahoo Finance closes $245.81 → $202.63; our calculation)2. Start of our coverage: Moderna falls 18% as strong cancer-vaccine data misses sky-high hopes | Merck release, WhyMyStockMoved |
| Oct 28, 2026 | Settles all US and European patent disputes with GSK, with cross-licences in infectious disease and no payments either way | 10-Q Q3 2026 |
| Nov 6, 2026 | Q3: revenue $1.31B (+29%), net income $162M; 2026 revenue growth guide raised to 15–25% and year-end cash to $8.1–8.3B | Q3 2026 release |
| Nov 12, 2026 | Analyst Day: oncology-led growth plan; cash costs of about $4B in 2027 and about $4–4.5B a year through 2030; the Ares loan extended to 2031 | Company release |
3. Latest quarter: did the story change?
Last updated Nov 12, 2026. Reflects Q3 2026 (quarter to Sep 30, released Nov 6; 10-Q filed Nov 6) against Q2, and the Nov 12 Analyst Day.
Bottom line: According to the Nov 6 release, Q3 revenue rose 29% to $1.31B on international COVID vaccine deliveries and Moderna made a quarterly profit; it raised its 2026 revenue growth outlook to 15–25% and cut its R&D outlook, but its norovirus vaccine will not get an additional group of trial participants this season.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Revenue | Q2 $145M → Q3 $1,313M (Q3 2025: $1,016M); COVID sales are seasonal | 2026 growth: up to 10% (Jul 31) → 15–25% (Nov 6) | Better |
| Operating costs | Research and development (R&D) $651M → $583M; selling, general and administrative (SG&A) $216M → $282M | 2026 R&D about $2.9B (Jul 31) → about $2.7B; SG&A about $1.0B, unchanged (Nov 6) | Better |
| Cash and investments | Jun 30 $6.9B → Sep 30 $8.0B, after $2.6B of net convertible-note proceeds and the $950M settlement payment | Year-end 2026: $4.7–5.2B (Jul 31) → $8.1–8.3B (Nov 6), including the notes | Better |
| Net income (loss) | Q2 −$782M → Q3 +$162M | No guide → no guide | Better |
| Norovirus vaccine (Phase 3) | Missed the early-success criteria at the interim analysis → no additional cohort this season; talking to health authorities about the path forward | Trial continues, another cohort to be enrolled (Jul 31) → no additional cohort this season (Nov 6) | Watch |
Sources: Q2 2026 release, Q3 2026 release, 10-Q Q3 2026.
Unresolved questions: when Moderna and Merck file intismeran for approval; how large the 2027 revenue base is (formal guidance comes with Q4 results); the outcome of the patent appeal.
4. Buybacks vs real dilution (5 years)
Last updated Nov 12, 2026. Reflects the equity statements in the 10-Ks for 2021 to 2025 and the 10-Q Q3 2026.
Dilution in one line: From Dec 31, 2020 to Dec 31, 2025 the share count fell 1.2%, about 0.24% a year compounded (our calculation)3. If you owned 1% of Moderna at the end of 2020, you’d own about 1.01% at the end of 2025 without buying more (our calculation)4. Buybacks offset about 116% of the estimated new shares from employee stock plans (our calculation)5. Our scale: Net reduction (the share count fell).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2020
Shares outstanding at period end (all classes): 398.8M on Dec 31, 2020, 394.0M on Dec 31, 2025, −1.2% (our calculation). A bar below zero means the count fell (net buybacks).
Latest quarter-end (Sep 30, 2026): 404.0M shares, +2.5% since Dec 31, 2025.
Dec 31, 2020 count from the author's bridge (10-K equity statement): 398.79M.
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| FY2025 (Dec 31, 2025) | 394.0M | +2.1% | $2M | $483M | 25% |
| FY2024 (Dec 31, 2024) | 386.0M | +1.0% | $0 | $429M | 13% |
| FY2023 (Dec 31, 2023) | 382.0M | −0.8% | $1.2B | $305M | 4% |
| FY2022 (Dec 31, 2022) | 385.0M | −4.5% | $3.3B | $226M | 1% |
| FY2021 (Dec 31, 2021) | 403.0M | +1.1% | $857M | $142M | 1% |
| FY2020 (Dec 31, 2020) | 398.8M | — | $0 | $93M | 12% |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
- Buybacks of about 34.8M shares compare with an estimated 30.1M new shares from employee stock plans.
- Since buybacks stopped in 2023 the count has risen, from 382M to 404.6M at Oct 30, 2026 (about 2.1% a year; our calculation)6.
How we calculated this
| Share bridge, Dec 31, 2020 → Dec 31, 2025 (disclosed equity statements; millions) | Shares |
|---|---|
| Start | 398.8 |
| + Stock options exercised | +17 |
| + Restricted stock units (share awards delivered when vesting conditions are met) vested | +11 |
| + Employee stock purchase plan | +1 |
| − Shares repurchased (2021–23; $5.34B spent) | −34.8 |
| End | 394 (−1.2%) |
| Shares issued for acquisitions, convertibles or offerings | None in the period |
Moderna reports share counts in millions in its equity statements, so components are rounded and may not sum exactly. The start is the exact 398,787,678 from the 10-K 2020. The repurchase total is our calculation from the table below.
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2021 | 3.5M | $245.76 | $857M | — | — | — | 10-K 2021: 3.5M shares; average price from the 10-K 2022 buyback note |
| 2022 | 23.3M (our calculation) | $142.83 | $3,329M | — | — | — | 10-K 2022 buyback note; shares are our calculation7 |
| 2023 | 8.0M (our calculation) | $143.26 | $1,153M | — | — | — | 10-K 2023 buyback note; includes excise tax; shares are our calculation8 |
| 2024 | — | — | — | — | — | — | 10-K 2025 buyback note |
| 2025 | — | — | — | — | — | — | 10-K 2025 buyback note |
| 2026 YTD (to Sep 30) | — | — | — | — | — | — | 10-Q Q3 2026 |
Moderna bought back shares only in 2021–23 and sold no shares through offerings or at-the-market programmes from 2021 through Sep 30, 2026; employee-plan issuance is excluded.
- Average prices are the company’s own and include related expenses.
- Moderna has not split its stock.
- It sold no shares for cash through offerings or at-the-market programmes in 2021 through Sep 30, 2026; employee-plan issuance is excluded.
- $1.7B of buyback authorisation remains, with no expiry.
- For reference, Nasdaq reports a closing price of $231.35 on Nov 12, 2026 (historical prices); Yahoo Finance shows the same close.
The $3.0B of convertible notes sold in September 2026 can turn into new shares equal to about 3.5% of those outstanding at the base conversion rate (our calculation)9; from Q1 2027 they may become convertible if the share price meets a set test, or earlier on other specified triggers (8-K).
Convertible-note dilution
- The $3.0B of convertible notes sold in September 2026 can turn into about 14.25M shares at about $210.58 each, or up to 21.0M shares in some cases; that is about 3.5% of the 404.6M shares outstanding on Oct 30, 2026 (our calculation)9.
- Moderna can settle conversions in cash, shares or both.
- It paid $328.8M for capped calls, purchased options meant to offset dilution or cash payments on conversion up to about $392.62 a share (8-K).
| Diluted shares and stock pay (disclosed; % is our calculation) | 2021 | 2022 | 2023 | 2024 | 2025 | 9M 2026 |
|---|---|---|---|---|---|---|
| Weighted diluted shares (M)* | 431 | 416 | 382 | 384 | 389 | 398 |
| Stock-based pay ($M) | 142 | 226 | 305 | 429 | 483 | 351 |
| Stock pay as % of revenue10 | 0.8% | 1.2% | 4.5% | 13% | 25% | 19% |
*Loss periods (2023 onward, including the first nine months of 2026) show no dilution from awards, so diluted shares equal basic; Q3 2026 alone, a profitable quarter, had 430M diluted shares.
5. Profit vs cash (latest FY and TTM)
Last updated Nov 12, 2026. Reflects the 10-K 2025 and the Q3 2026 release. TTM = the four quarters to Sep 30, 2026 (our calculation)11.
Moderna loses money and burns cash. In the 12 months to Sep 30, 2026, cash burn included the $950M patent settlement paid in July and about $1.2B of Q3 sales not yet collected at quarter-end, which Moderna says are seasonal. Moderna does not report an adjusted profit measure.
| $M | 2025 (disclosed unless marked) | TTM (our calculation) |
|---|---|---|
| Net loss | −2,822 | −2,789 |
| Operating cash flow | −1,873 | −1,785 |
| Capital spending | −192 | −185 |
| Free cash flow (our calculation)12 | −2,065 | −1,970 |
Helps future profit or cash:
- Receivables: $1,367M at Sep 30, 2026, up from $184M at Dec 31, 2025; most Q3 sales were uncollected at quarter-end, so the cash arrives when customers pay (receivables took $1,184M of operating cash in the first nine months).
- Customer prepayments (deferred revenue $407M at Sep 30): cash received before revenue is recognised; recognising that revenue later brings no additional cash receipt.
Hurts future profit or cash:
- Stock pay ($483M in 2025, $464M TTM): a non-cash expense paid in shares, so it dilutes ownership rather than costing cash.
- Depreciation and amortisation ($215M in 2025, $257M TTM): lowers reported profit each year but is not a cash cost.
One-off / no lasting effect:
- The patent settlement: the $950M was paid in July 2026; in Q1 Moderna expensed $876M and capitalised $74M as a licence asset, amortised over about three years (Q1 2026 10-Q, note 12).
- The $2.6B of net convertible-note proceeds (September) are financing, not operating cash, so they are not in free cash flow.
The raw reconciling items
- Stock pay is a non-cash expense: $483M in 2025 ($464M TTM).
- Depreciation and amortisation added back $215M in 2025 ($257M TTM).
- The $950M settlement accrued in Q1 2026 was paid in July 2026 (10-Q).
- Receivables used $1,184M in the first nine months of 2026; deferred revenue added $160M (Q3 2026 release, cash flow statement).
Funding: how long without new money? Cash-burning: cash, cash equivalents and investments of about $7.98B at Sep 30, 2026 covered about 7.3 years of TTM free cash outflow excluding the one-off settlement payment, or about 4.0 years including it (our calculation)13; at the adjusted past rate and with known items, cash would not fall below zero within 5 years. Moderna separately guides to cash costs of about $4B in 2027 and $4–4.5B a year through 2030.
Funding details
- As of Sep 30, 2026. Based on past cash flow; spending plans can change it. Moderna expects year-end 2026 cash and investments of about $8.1–8.3B, excluding further loan draws (Q3 2026 release), and about $9B of total liquidity including undrawn borrowing capacity (Analyst Day release).
- Debt and convertible notes due within 24 months: none. The $600M term loan’s maturity was extended by one year to 2031 on Nov 12 (Analyst Day release); the $3.0B of 0% convertible notes are due Mar 1, 2032.
- At-the-market share-sale programme: none disclosed.
Extends the runway:
- About $900M of undrawn delayed-draw term loans under the Ares-led facility, whose availability Moderna extended through 2029 on Nov 12, with the interest rate on drawn amounts cut by 0.75 points (Analyst Day release). The 10-Q (before that change) splits it into $400M available through Nov 24, 2027 and $500M through Nov 24, 2028 subject to regulatory milestones (10-Q). Shown in the financing table below the cash path.
Shortens the runway:
- Finance-lease principal of $27M due within 12 months (in the cash path).
- The $600M term loan (due 2031 after the amendment) and the $3.0B convertible notes (due 2032) fall after the window.
Conditional:
- If the appeals court rules against Moderna on the patent case, it owes up to $1.3B more within 90 days (8-K; 10-Q); not accrued, and not included below.
- Blackstone: low single-digit royalties on influenza and combination-vaccine net sales, plus up to $750M of sales milestones; none accrued at Sep 30, 2026 (10-Q).
Cash path (our calculation; an illustration, not a forecast):
At the adjusted past rate and with known items, cash would not fall below zero within 5 years (with the settlement left in the past rate, it would in Q4 2030)14.
Illustration, not a forecast.
- 1 · Q4 2026 · Financing-lease principal −$27M
- 2 · Cash if drawn: $3.38B at Q3 2031
Ending cash (cash, equivalents and marketable securities) Known item If committed financing is drawn
| Quarter | Starting cash | Usual spending | Known items | Ending cash | Sources / notes |
|---|---|---|---|---|---|
| Q4 2026 | +7,976.0 | −273.5 | −27.0 | +7,675.5 | Financing-lease principal: −$27M. Conservative timing assumption: all remaining principal is reserved here; disclosed gross payments are $9M in Q4 2026 and $19M in 2027, including $1M of interest, and quarterly principal is not disclosed (10-Q, note 10) |
| Q1 2027 | +7,675.5 | −273.5 | 0.0 | +7,402.0 | |
| Q2 2027 | +7,402.0 | −273.5 | 0.0 | +7,128.5 | |
| Q3 2027 | +7,128.5 | −273.5 | 0.0 | +6,855.0 | |
| Q4 2027 | +6,855.0 | −273.5 | 0.0 | +6,581.5 | |
| Q1 2028 | +6,581.5 | −273.5 | 0.0 | +6,308.0 | |
| Q2 2028 | +6,308.0 | −273.5 | 0.0 | +6,034.5 | |
| Q3 2028 | +6,034.5 | −273.5 | 0.0 | +5,761.0 | |
| Q4 2028 | +5,761.0 | −273.5 | 0.0 | +5,487.5 | |
| Q1 2029 | +5,487.5 | −273.5 | 0.0 | +5,214.0 | |
| Q2 2029 | +5,214.0 | −273.5 | 0.0 | +4,940.5 | |
| Q3 2029 | +4,940.5 | −273.5 | 0.0 | +4,667.0 | |
| Q4 2029 | +4,667.0 | −273.5 | 0.0 | +4,393.5 | |
| Q1 2030 | +4,393.5 | −273.5 | 0.0 | +4,120.0 | |
| Q2 2030 | +4,120.0 | −273.5 | 0.0 | +3,846.5 | |
| Q3 2030 | +3,846.5 | −273.5 | 0.0 | +3,573.0 | |
| Q4 2030 | +3,573.0 | −273.5 | 0.0 | +3,299.5 | |
| Q1 2031 | +3,299.5 | −273.5 | 0.0 | +3,026.0 | |
| Q2 2031 | +3,026.0 | −273.5 | 0.0 | +2,752.5 | |
| Q3 2031 | +2,752.5 | −273.5 | 0.0 | +2,479.0 |
Amounts in $M.
Financing that could extend the runway (committed, not yet drawn; not in the cash path above):
| Quarter | Financing that could extend the runway | Amount | Conditions | Source |
|---|---|---|---|---|
| Q4 2029 | Undrawn delayed-draw term loans under the Ares-led facility | +900.0 | Availability extended through 2029 (Nov 12); before the amendment, $500M of it required specified regulatory milestones | Analyst Day release; 10-Q Q3 2026 |
At the adjusted past rate and with known items, cash would not fall below zero within 5 years (with the settlement left in the past rate, it would in Q4 2030)14. Moderna says its resources, including expected product receipts and available borrowing, fund projected operations and capital spending for at least 12 months from the filing (10-Q); that is a minimum assurance, not a run-out date. Its separate cash-cost guidance (about $4B in 2027 and $4–4.5B a year through 2030, mainly oncology; Analyst Day release) is gross spending, not net cash burn. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.
What the cash path counts:
- Usual spending: −$273.5M a quarter, held flat (TTM free cash flow excluding the $876M of the settlement that went through operating cash flow).
- Known items: $27M of finance-lease principal due within 12 months. The term loan (2031) and convertible notes (2032) fall after the window.
How we calculated this
- Usual spending = (TTM free cash flow −$1,970M + $876M) ÷ 4 = −$273.5M a quarter, held flat, under the lumpy one-offs rule: of the $950M settlement paid in July 2026, $876M was expensed and paid through operating cash flow and $74M bought a licence (an intangible asset, outside our free-cash-flow measure) (Q1 2026 10-Q, note 12); unadjusted, it would be −$492.5M a quarter and cash would fall below zero in Q4 2030 (our calculation)14. Starting cash is cash, cash equivalents and investments at Sep 30, 2026.
- The convertible-note proceeds are already in starting cash.
- Operating-lease, purchase and interest payments are in operating cash flow, so they are already in usual spending.
- Capital spending is already in free cash flow; TTM capex of $185M is in line with the company’s 2026 plan of about $0.2B (Q3 2026 release).
- Company framework: “Cash costs are defined as GAAP [US generally accepted accounting principles] expenses less stock-based compensation and depreciation and amortization” (Analyst Day release). Cash costs are not free cash flow: revenue and working capital offset part of them, so the two cannot be compared directly.
- The earlier target of cash breakeven in 2028 (8-K, Jan 12) is not repeated in the Nov 12 Analyst Day release.
6. Customer and contract exposure
Last updated Nov 12, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026.
A few distributors and governments make up a large share of revenue, and the largest buyers change from year to year: the largest single customer in 2023–25 was 21% of revenue (Japan, 2023), and the three above 10% in 2025 were two distributors and the Canadian government.
Chart source15.
| Customers at more than 10% of revenue (disclosed, named) | 2023 | 2024 | 2025 |
|---|---|---|---|
| FFF Enterprises (US distributor) | <10% | 13% | 15% |
| Public Works and Government Services Canada | <10% | <10% | 13% |
| Cardinal Health (US distributor) | <10% | <10% | 11% |
| UK Health Security Agency | <10% | 16% | <10% |
| Japan’s Ministry of Health, Labour and Welfare | 21% | <10% | <10% |
Customer and contract details
- At Dec 31, 2025, three buyers held most receivables: the Canadian government (33%), Mexico’s Medistik (29%) and Boryung Biopharma Korea (17%). Disclosed.
- The UK, Canadian and Australian governments have multi-year commitments to buy mRNA products from Moderna-built local factories, licensed in 2025. Part of the payment is booked as stand-ready manufacturing revenue. Contract lengths and amounts are not disclosed in the 10-K.
- In Q2 2026 Moderna signed an EU joint procurement contract for up to 24M doses of mRESVIA for six countries, and announced long-term agreements with Mexico and Taiwan in early 2026 (Q2 release, Q4 2025 release).
- Merck shares intismeran’s costs and any profits or losses equally worldwide. Recordati is to sell the propionic acidemia candidate if approved.
- Deferred revenue from customer advance payments was $407M at Sep 30, 2026, and receivables were $1,367M, mostly from Q3 sales (Q3 2026 release). Disclosed.
- In September 2026 Moderna signed a five-year agreement with a local manufacturer in Mexico for COVID-19 vaccines (Q3 2026 release).
7. Strategy for long-term growth
Last updated Nov 12, 2026. Reflects the Q3 2026 release and 10-Q and the Nov 12 Analyst Day release.
Moderna’s plan is to keep its infectious-disease vaccines growing and more profitable while putting most new spending into cancer medicines, led by intismeran; it has not yet published revenue targets beyond 2026.
- Pressures on the core business: COVID vaccine product sales fell from $17.7B in 2021 to $1.81B in 2025; sales are seasonal and concentrated in a few buyers; patent disputes continue, with GSK settled on Oct 28, 2026 but CureVac suits pending (10-Q).
- Strategy: management’s stated goals are revenue growth, better vaccine profitability, disciplined investment in oncology and other pipeline programmes, and a strong balance sheet (Analyst Day release); in its words, “The Company will continue to reinvest cash flow in the infectious disease vaccine pipeline with discipline.”
- Oncology: intismeran’s Phase 3 melanoma trial met its main goal (42% lower risk of recurrence or death); Moderna and Merck plan to co-promote it in the US, with Merck leading elsewhere; the Marlborough site is expected to become its global supply site in 2027. Other cancer programmes (mRNA-4359 in Phase 2; mRNA-4106, mRNA-4200 and mRNA-4194 earlier) are in trials (Analyst Day release; Q3 2026 release).
- Spending: cash costs of about $4B in 2027 and about $4–4.5B a year from 2027 through 2030, “driven mainly by oncology investment”; the 2027 cost framework was brought forward into 2026 (Analyst Day release).
- How it is working, in numbers: Q3 2026 revenue +29%; 2026 growth guide raised to 15–25%; R&D guide cut to about $2.7B; about 10 points of 2026 gross margin (sales less cost of sales, as a share of sales) expansion, excluding the settlement charge (Q3 2026 release; Analyst Day release). Revenue from the newer products (mFLUSIVA, the combination vaccine) is not disclosed separately; mFLUSIVA sales were immaterial in Q3 (10-Q).
- Setbacks: the norovirus vaccine missed its interim early-success test and gets no new cohort this season; the US combination-vaccine filing awaits FDA guidance (Q3 2026 release).
8. What to watch
Last updated Nov 12, 2026. Reflects the 10-Q for Q3 2026 and company announcements through Nov 12, 2026.
| Date | Item | Source |
|---|---|---|
| Late 2026 (company expectation) | Results from a study intended to support an application for regulatory approval (a registrational study) of mRNA-3927, an investigational treatment for propionic acidemia, a rare inherited metabolic disorder | Analyst Day release |
| Early 2027 (date not announced) | Q4 results, with formal 2027 financial guidance | Analyst Day release |
| Date not set | Regulatory submissions for intismeran with Merck, after the Phase 3 melanoma results | Q3 2026 release |
| 2027–2028 respiratory season | A broader launch of the flu vaccine mFLUSIVA, after a limited 2026–27 US launch | Analyst Day release; Q3 2026 release |
| Date not set | Federal Circuit ruling on Moderna’s patent appeal (No. 26-1581): up to $1.3B due within 90 days if Moderna loses | 8-K, 10-Q |
| Q1 2027 onward | Conversion of the 2032 notes may become available if the share price meets a test: at least 150% of the conversion price on 20 of the last 30 trading days of the previous quarter; other contractual triggers can also permit conversion | 8-K |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $202.63 (Oct 22) | $80.8B | $74.6B† | 36.3× | 33.5× | n/m | n/m | −28% | −56% | $6.3B† | 12 months to Jun 30, 2026 |
| Nov 12, 2026 | $231.35 (Nov 12) | $93.6B | $89.2B† | 37.1× | 35.3× | n/m | n/m | +13% | −78% | $4.4B† | 12 months to Sep 30, 2026 |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026: † Debt excludes a $14M research and development funding liability to Blackstone, which Moderna reports separately. Nov 12, 2026: † Debt excludes an $8M research and development funding liability to Blackstone, which Moderna reports separately. Oct 27, 2026 row: Updated Nov 12, 2026: debt now includes $37M of finance leases (now $628M, was $591M), on the same basis as later snapshots; net cash is $6.28B (was $6.32B) and enterprise value $74.57B (was $74.53B). Price, date and the rounded ratios are unchanged. Nov 12, 2026 price: Nasdaq historical close.
Notes and calculations
-
174.38 ÷ 62.96 − 1. ↩
-
202.63 ÷ 245.81 − 1. ↩
-
Change = 394 ÷ 398.79 − 1; annual rate = (394 ÷ 398.79)^(1/5) − 1. ↩
-
1% × 398.79M ÷ 394M. ↩
-
Repurchases = 857 ÷ 245.76 + 3,329 ÷ 142.83 + 1,153 ÷ 143.26 = 34.84M; new shares = 394 − 398.79 + 34.84 = 30.06M, using the rounded ending count (unrounded: 394 − 398.787678 + 34.842874 = 30.055196M); offset = 34.84 ÷ 30.06 ≈ 116%. ↩
-
(404.6 ÷ 382)^(1 ÷ 2.83) − 1, from Dec 31, 2023 to Oct 30, 2026 (404,620,975 shares on the 10-Q cover). ↩
-
$3,329M ÷ $142.83. ↩
-
$1,153M ÷ $143.26. ↩
-
Stock pay ÷ revenue; 9M 2026: $351M ÷ $1,847M. ↩
-
TTM = 2025 − 9M 2025 + 9M 2026. Net loss −$2,822M + $1,996M − $1,963M = −$2,789M. Operating cash flow −$1,873M + $2,803M − $2,715M = −$1,785M. Capital spending −$192M + $153M − $146M = −$185M. Stock pay $483M − $370M + $351M = $464M. D&A $215M − $148M + $190M = $257M. ↩
-
Operating cash flow − capital spending. ↩
-
Cash and investments $1,195M + $3,976M + $2,805M = $7,976M. $7,976M ÷ ($1,970M − $876M) = 7.3 years; $7,976M ÷ $1,970M = 4.0 years. ↩
-
Unadjusted (TTM free cash flow −$1,970M ÷ 4 = −$492.5M a quarter): $7,976M − $27M − 16 × $492.5M = +$69.0M at the end of Q3 2030; Q4 2030 ends at −$423.5M. ↩ ↩2
-
Accessed Oct 27, 2026: 10-K 2025 (customers above 10% of revenue). Customers below 10% in a year are not charted. ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About Moderna: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)